Please assess the completion status of the following clinical trial:

Trial Title: S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Morphologically confirmed acute myeloid leukemia (AML) (within 180 days of diagnosis) OR~* Secondary AML (secondary to myelodysplastic syndromes (MDS) or to prior leukemogenic therapy)~* Must have A1 marrow, B1 blood, and C1 extramedullary disease status~* Must have received prior remission induction chemotherapy~* Must have a genotypically HLA-identical sibling donor available that is not a monozygotic identical twin~* No M3 AML or blastic transformation of chronic myelogenous leukemia~* If history of CNS leukemia, no leukemia cells in CNS by lumbar puncture within past 7 days~* Must be concurrently enrolled on protocols SWOG-9007 and SWOG-S9910~PATIENT CHARACTERISTICS:~Age~* 55 to 69~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* See Disease Characteristics~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* No other malignancy within the past 2 years except for the following:~  * Adequately treated basal cell or squamous cell skin cancer~ * Carcinoma in situ of the cervix~ * Adequately treated stage I or II cancer in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior allogeneic hematopoietic stem cell transplantation~Chemotherapy~* See Disease Characteristics~* Prior consolidation therapy allowed~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Prior organ transplantation allowed provided not concurrently receiving immunosuppressive therapy

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): patient conditioning - fludarabine 30 mg/m2 IV over 1 hour Days -4, -3, -2; TBI 6-7 cGy/min Day 0 post-transplant immunosuppression - cyclosporine 6.25 mg/kg bid PO D -3 to +180 (begin taper on D+35); mycophenolate mofetil 15mg/kg bid PO D0 to +27

Based on this trial design, predict the completion outcome and termination type (if applicable).